Trial of Adjunctive Vitamin D in Tuberculosis Treatment

Trial of Adjunctive Vitamin D in Tuberculosis Treatment

The purpose of this study is to determine whether vitamin D enhances response to standard antibiotic treatment for pulmonary tuberculosis.

Inclusion Criteria:

• Suspected smear positive pulmonary tuberculosis.
• Age 18 years or older.
• Written informed consent to participate.

Exclusion Criteria:

• Known intolerance of vitamin D or first-line anti-tuberculous therapy.
• Taking antituberculous therapy for more than six days in the six months preceding enrolment.
• Taking the following medication in the month preceding enrolment: oral corticosteroid therapy, immunosuppressant therapy or cytotoxic therapy.
• Taking the following medication at enrolment: benzothiadiazine derivatives, cardiac glycosides or antituberculous therapy other than rifampicin, isoniazid, pyrazinamide and ethambutol.
• Diagnosis of any of the following: sarcoidosis, hyperparathyroidism, nephrolithiasis, pulmonary silicosis, HIV infection, liver failure, renal failure or malignancy
• Infection with rifampicin-resistant organism (as demonstrated by rapid molecular testing)
• Biochemical disturbance at enrolment: serum corrected calcium >2.66 mmol/l, serum AST >120 IU/l, total serum bilirubin > 40 micromol/l or serum creatinine > 250 micromol/l
• Breastfeeding or pregnancy